While the Oncology segment did well, led by a ramp up in Ibrance sales, most of the other pharmaceuticals segments saw revenue declines. Expect Oncology To Drive Near Term GrowthTrefisPfizer’s Oncology segment posted a 23% jump (y-o-y) in Q1 sales, primarily led by a ramp up in Ibrance sales. Ibrance has been approved for the treatment of breast cancer, which is the most prevalent cancer type in women. An estimated 266,120 new cases of invasive breast cancer, and 63,960 new cases of non-invasive breast cancer, are expected to be diagnosed in women in the U.S. this year. Apart from Ibrance, Pfizer’s Xalkori is doing well, targeting a certain type of non-small cell lung cancer.

Source: Forbes May 04, 2018 18:45 UTC